| Mobile Web

All articles List

AI & Enterprise

Fully AI-designed new drugs are only a matter of time, AstraZeneca blueprint shows

Artificial intelligence is becoming core infrastructure in biopharmaceutical development, rapidly changing how drug candidates are found and validated. AstraZeneca says computing now reinforces the entire process from design and production to verification and analysis, shortening development cycles and boosting productivity. The company uses a build-measure-learn loop, multimodal datasets and precision screening, and is building an AI- and robot-enabled lab in Cambridge, Massachusetts. Executives say de novo, fully AI-generated biologics are an industry goal but require richer data, benchmarks and talent, with human oversight remaining central.

Industry

China expands AI cobots working with people from manufacturing to services

Adoption of AI-based collaborative robots, or AI cobots, is rising quickly in China as robot makers expand beyond traditional industrial machines, the South China Morning Post reported. Cobots are designed to work alongside people and are evolving with AI to recognise environments and respond to workflows. Their use is spreading from production lines to customer service, guidance and office support. Industry participants say safety, accuracy, maintenance costs and training still need verification.

Finance

Financial holding brokerages post about 1.41 trillion won Q2 net profit on brokerage boom

Brokerages under South Korean financial holding groups posted a combined net profit of about 1.41 trillion won in the second quarter, helped by increased stock market turnover, the investment industry said on Thursday. NH Investment & Securities and KB Securities set quarterly record results, while Shinhan Investment and Hana Securities extended growth on higher brokerage income. Woori Investment & Securities posted lower quarterly profit due to higher bad-debt costs.